Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO
August 21, 2024 09:00 ET
|
GeoVax, Inc.
Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax...
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
August 15, 2024 09:00 ET
|
GeoVax, Inc.
Company to Discuss Recent Mpox Developments as Well as Milestones Related to theBARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine ATLANTA, GA, Aug. 15, 2024 (GLOBE NEWSWIRE) --...
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
August 08, 2024 09:00 ET
|
GeoVax, Inc.
Strategic Appointment Enhances GeoVax’s Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
April 04, 2024 12:30 ET
|
GeoVax, Inc.
Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
March 28, 2024 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
January 04, 2024 09:00 ET
|
GeoVax, Inc.
Therapy Demonstrated Safety, Stabilization/Shrinkage of Treated Tumors Expanded Development for Monotherapy and Combination Therapy Anticipated ATLANTA, GA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via...
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
December 19, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax to Participate in Upcoming December Investor Events
November 29, 2023 09:00 ET
|
GeoVax, Inc.
ATLANTA, GA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
November 14, 2023 09:00 ET
|
GeoVax, Inc.
Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023
October 31, 2023 09:00 ET
|
GeoVax, Inc.
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing...